Bladder Cancer VL

Adequate BCG Therapy for Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Analysis - José Daniel Subiela Henriquez

Details
José Daniel Subiela Henriquez presented findings from his multicenter study on BCG therapy for very high-risk non-muscle-invasive bladder cancer (NMIBC). Dr. Subiela's research evaluates the effectiveness of BCG in a group where the European Association of Urology (EAU) had recommended radical cystectomy due to high progression risks. His study, involving 640 patients over 13 years, suggests that...

Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan

Details
Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. Microhematuria, a common condition affecting millions annually in the U.S., is frequently o...

Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li

Details
Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. The trial explores the combination of cretostimogene grenadenorepvec, an oncolytic immunotherapy, with pembrolizumab. This combination shows...

CORE-001 Study: Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li

Details
Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...

Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie

Details
Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...

KEYNOTE-676 Cohort A: Pembrolizumab + BCG for Previously BCG-Treated NMIBC - Neal Shore

Details
Sam Chang interviews Neal Shore about the KEYNOTE-676 trial. This global study evaluates the efficacy of combining Pembrolizumab with BCG induction and maintenance in patients who had previously received an induction course of BCG without maintenance. Dr. Shore discusses the study’s aim to enhance the effectiveness of BCG therapy in non-muscle invasive bladder cancer (NMIBC) by adding a checkpoint...

AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser

Details
Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....

SSANTROP Trial: Evaluating Sacituzumab Govitecan and Sasanlimab for BCG-Unresponsive Bladder Cancer - Oscar Rodriguez-Faba

Details
Sam Chang interviews Oscar Rodriguez-Faba about the SSANTROP trial. This phase II trial assesses the efficacy of combining sacituzumab govitecan, a monoclonal antibody targeting the Trop-2 receptor, with the PD-1 inhibitor sasanlimab in BCG-unresponsive non-muscle-invasive bladder cancer. The trial aims to provide a systemic therapy alternative to radical cystectomy, with a sample size goal of 120...

Exploring the Complexities of Bladder Cancer Surveillance: Cytology, UroVysion, and Beyond - Komal Pohar & Kelly Bree

Details
Ashish Kamat engages with Kamal Pohar and Kelly Bree on bladder cancer surveillance. They discuss the ongoing debate about the utility of various urinary markers in monitoring bladder cancer. Dr. Pohar mentions his reliance on cytology, while Dr. Bree adds that she uses cytology and occasionally UroVysion FISH for atypical cases, and also blue light cystoscopy despite its challenges. They both hig...

The Evolving Role of Radical Cystectomy in the Era of Bladder-Sparing Therapies - Sima Porten & Roger Li

Details
Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. Dr. Porten highlights the importance of discussing radical cystectomy as the gold standard while also considering bladder-preserving treatments depending on the patient's disease characteris...